Show
Sort by
-
Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS
-
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps
-
Current controversies and challenges in allergic rhinitis management
-
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis
-
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
-
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis